FDA Lifts Clinical Hold on ARD-101 Drug Program
The regulatory update allows San Diego-based Aardvark Therapeutics to plan for the resumption of its clinical development.
Updated on Oct. 22, 2026 in Heart Disease
Live Poll
Should pharmaceutical companies be required to prioritize safety testing over faster drug development timelines?
The FDA has officially lifted the clinical hold on the ARD-101 drug program following a review of new cardiac safety data. This move allows San Diego-based Aardvark Therapeutics to resume development plans for the treatment.
Why it matters
The development provides a path forward for the ARD-101 program after safety concerns regarding electrocardiogram changes prompted a voluntary pause and subsequent federal hold earlier this year. Patients awaiting new therapeutic options may see clinical trials restart once the company aligns with federal regulators on study designs.
Aardvark Therapeutics conducted an ECG study in healthy volunteers and an in vitro cardiac sodium channel study to evaluate safety. No cardiac events occurred at 200 mg and 400 mg twice-daily doses, providing data that helped clear the federal hold on the drug program.
The players
Aardvark Therapeutics
A San Diego-based pharmaceutical company focused on the development of ARD-101.
FDA
The federal agency responsible for overseeing the safety and efficacy of drug development programs in the United States.
The details
The clinical hold was initiated in May 2026 after researchers observed reversible electrocardiogram changes in a separate study. To address these concerns, the company unblinded data from the HERO and OLE trials and performed specialized cardiac testing. These assessments were designed to confirm whether the drug impacts the cardiac sodium channel, a critical component of heart rhythm regulation.
Timeline
February 27, 2026: Aardvark voluntarily paused dosing in clinical trials.
May 2026: The FDA placed a clinical hold on the trials.
October 22, 2026: The FDA lifted the clinical hold on ARD-101.
October 23, 2026: Aardvark hosts a conference call and webcast to discuss trial data.
Health Landscape
The lifting of the hold marks a significant shift in the trajectory of the ARD-101 development program. It updates the status of the therapy relative to the 2026 regulatory intervention, shifting focus toward re-aligning Phase 3 study designs with federal oversight requirements.
If you are following developments for this specific investigational treatment, note that clinical trials are currently in a planning phase. Further updates regarding trial participation or availability should be discussed with your physician or monitored through official clinical trial registries.
The takeaway
The lifting of the FDA hold clears the way for Aardvark Therapeutics to finalize new trial designs for ARD-101. Interested patients should keep in mind that the drug remains in the clinical development stage and is not available for standard medical use.
Further reading
For more on evolving standards for safety in clinical trials, see our Heart Disease section.
Live Poll
Should pharmaceutical companies be required to prioritize safety testing over faster drug development timelines?
